Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at
50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to
imatinib.